Expedited Partner Therapy (EPT) has been shown to reduce rates of persistent or recurrent
gonorrhea and chlamydia infection in heterosexual patients, but has not been evaluated for
use among men who have sex with men (MSM). CDC guidelines support the use of EPT for partner
management with heterosexual patients, but note the absence of evidence necessary to make an
equivalent recommendation for the use of EPT with MSM. Randomized clinical trials to assess
the impact of EPT on partner notification, treatment, and STI re-infection among MSM are
critical to the development of evidence-based partner management guidelines.
Recent data from urban Peru has identified prevalences of rectal and pharyngeal gonorrhea and
chlamydia ranging from 5-20%. The elevated burden of disease among MSM in Peru suggests that
frequent transmission of undiagnosed gonorrhea and chlamydia through MSM sexual networks may
be a factor contributing to the persistently high incidence of HIV infection among MSM in the
region. The investigators propose a pilot evaluation of the effect of EPT on partner
notification and treatment among MSM in Peru diagnosed with gonorrhea or chlamydia at any
Specific Aim 1: To explore the social norms and structural factors influencing partner
notification and treatment among MSM in Peru.
Specific Aim 2: To determine the effect of EPT on anticipated and actual partner notification
among MSM diagnosed with gonorrhea or chlamydia infection.
Specific Aim 3: To develop preliminary data on rates of gonococcal and chlamydial
re-infection among MSM randomized to receive EPT compared with standard partner notification
The proposed study will provide pilot data on the use of EPT with MSM diagnosed with
gonorrhea or chlamydia and form the basis for a subsequent Phase III clinical trial of EPT as
an STI control method among MSM in Latin America.